Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
While cross-trial comparisons come with important caveats patient populations, trial designs, and dose titrations all differ the overall pattern is clear
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Pharmacokinetics & Metabolism Absorption & Distribution The CJC-1295 (NO DAC) + Ipamorelin blend peptide exhibits distinct pharmacokinetic profiles for each component when administered in research settings: CJC-1295 (NO DAC): Subcutaneous administration results in gradual absorption with peak plasma concentrations within 1-4 hours Half-life of approximately 30 minutes to 2 hours enables pulsatile growth hormone stimulation Distribution throughout systemic circulation with selective binding to pituitary GHRH receptors Bioavailability significantly improved compared to native GHRH due to enhanced enzymatic resistance Ipamorelin: Rapid absorption following subcutaneous administration with peak levels at approximately 40 minutes Terminal half-life of approximately 2 hours in human pharmacokinetic studies Dose-proportional pharmacokinetic parameters across studied dose ranges Volume of distribution at steady-state of 0.22 L/kg indicating limited tissue distribution When administered together, ipamorelin provides rapid-onset growth hormone pulse generation (peak at 0.67 hours) while CJC-1295 maintains elevated baseline growth hormone levels through sustained GHRH receptor activation
Benefits include: Improved glycemic control Reduced blood pressure Improved lipid profiles Reduced systemic inflammation Improved insulin sensitivity Reduced cardiovascular risk The SELECT trial may ultimately prove to be a turning point in employer health strategy
Injections For the injections, blood tests are done before prescribing it
Direct mechanisms may involve GLP-1 receptor activation on vascular endothelial cells, whilst indirect effects result from weight loss, improved glycaemic control, and reduced visceral adiposity, all of which independently lower inflammatory burden
